Ritu Baral
Stock Analyst at TD Cowen
(3.13)
# 1,502
Out of 5,182 analysts
45
Total ratings
41.46%
Success rate
4.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HELP Cybin | Initiates: Buy | $8 | $5.61 | +42.60% | 1 | Apr 13, 2026 | |
| TERN Terns Pharmaceuticals | Downgrades: Hold | $53 | $52.74 | +0.49% | 2 | Mar 26, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $37 | $22.09 | +67.50% | 3 | Feb 26, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $202 → $306 | $276.50 | +10.67% | 1 | Jan 9, 2026 | |
| VTVT vTv Therapeutics | Initiates: Buy | $67 | $37.75 | +77.48% | 1 | Jan 5, 2026 | |
| INSM Insmed | Maintains: Buy | $269 → $241 | $142.82 | +68.74% | 7 | Dec 18, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $97 → $133 | $129.33 | +2.84% | 3 | Dec 16, 2025 | |
| MIST Milestone Pharmaceuticals | Upgrades: Buy | $8 | $2.04 | +292.16% | 1 | Dec 15, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $251 → $353 | $342.57 | +3.04% | 1 | Dec 8, 2025 | |
| VERA Vera Therapeutics | Maintains: Buy | $60 → $73 | $41.61 | +75.44% | 2 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $390 → $554 | $527.11 | +5.10% | 2 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.84 | - | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.62 | - | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $282 → $371 | $310.94 | +19.32% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.44 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $175 | $21.42 | +716.99% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $69.90 | - | 2 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.29 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $21.50 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.90 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.29 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $403.75 | - | 2 | Jan 12, 2018 |
Cybin
Apr 13, 2026
Initiates: Buy
Price Target: $8
Current: $5.61
Upside: +42.60%
Terns Pharmaceuticals
Mar 26, 2026
Downgrades: Hold
Price Target: $53
Current: $52.74
Upside: +0.49%
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $35 → $37
Current: $22.09
Upside: +67.50%
Krystal Biotech
Jan 9, 2026
Maintains: Buy
Price Target: $202 → $306
Current: $276.50
Upside: +10.67%
vTv Therapeutics
Jan 5, 2026
Initiates: Buy
Price Target: $67
Current: $37.75
Upside: +77.48%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $269 → $241
Current: $142.82
Upside: +68.74%
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $97 → $133
Current: $129.33
Upside: +2.84%
Milestone Pharmaceuticals
Dec 15, 2025
Upgrades: Buy
Price Target: $8
Current: $2.04
Upside: +292.16%
Praxis Precision Medicines
Dec 8, 2025
Maintains: Buy
Price Target: $251 → $353
Current: $342.57
Upside: +3.04%
Vera Therapeutics
Dec 5, 2025
Maintains: Buy
Price Target: $60 → $73
Current: $41.61
Upside: +75.44%
Aug 26, 2025
Maintains: Buy
Price Target: $390 → $554
Current: $527.11
Upside: +5.10%
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.84
Upside: -
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $3.62
Upside: -
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $310.94
Upside: +19.32%
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $6.44
Upside: -
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $21.42
Upside: +716.99%
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $69.90
Upside: -
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.29
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $21.50
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.90
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.29
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $403.75
Upside: -